HIV-1 vector systems

Somatic Cell and Molecular Genetics

Volumn 26, Issue 1-6, 2001, Pages 51-81

  Srinivasakumar, Narasimhachar ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; INTEGRASE; LENTIVIRUS VECTOR; MATRIX PROTEIN; VIRUS RNA; VIRUS VECTOR; VPR PROTEIN;

CELL DIFFERENTIATION; CELL DIVISION; GENE TRANSFER; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRINAE; MOLONEY LEUKEMIA ONCOVIRUS; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; REVIEW; RNA TRANSCRIPTION; VIRUS DNA CELL DNA INTERACTION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS; MOLONEY MURINE LEUKEMIA VIRUS; MURINAE; MURINE LEUKEMIA VIRUS; ONCOVIRINAE; RNA VIRUSES;

EID: 0035525956     PISSN: 07407750     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1021074613196     Document Type: Review

References (208)

1. Coffin J.M., Stephen HH, Varmus HE. Retroviruses: CSHL; 1997.
2. Feinberg MB, Baltimore D, Frankel AD. The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. Proc Natl Acad Sci USA 1991; 88(9):4045-4049.
3. Gaynor RB. Regulation of HIV-1 gene expression by the transactivator protein Tat. Curr Top Microbiol Immunol 1995; 193:51-77.
4. Jeang KT, Xiao H, Rich EA. Multifaceted Activities of the HIV-1 Transactivator of Transcription, Tat. J Biol Chem 1999; 274(41):28837-28840.
5. Jones KA. Taking a new TAK on tat transactivation [comment]. Genes Dev 1997; 11(20):2593-2599.
6. Purcell DF, Martin MA. Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. J Virol 1993; 67(11):6365-6378.
7. Arrigo SJ, Weitsman S, Zack JA et al. Characterization and expression of novel singly spliced RNA species of human immunodeficiency virus type 1. J Virol 1990; 64(9):4585-4588.
8. Guatelli JC, Gingeras TR, Richman DD. Alternative splice acceptor utilization during human immunodeficiency virus type 1 infection of cultured cells. J Virol 1990; 64(9):4093-4098.
9. Muesing MA, Smith DH, Cabradilla CD et al. Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus. Nature 1985; 313(6002):450-458.
10. Robert-Guroff M, Popovic M, Gartner S et al. Structure and expression of tat-, rev-, and nef-specific transcripts of human immunodeficiency virus type 1 in infected lymphocytes and macrophages. J Virol 1990; 64(7):3391-3398.
11. Schwartz S, Felber BK, Benko DM et al. Cloning and functional analysis of multiply spliced mRNA species of human immunodeficiency virus type 1. J Virol 1990; 64(6):2519-2529.
12. Schwartz S, Felber BK, Fenyo EM et al. Env and Vpu proteins of human immunodeficiency virus type 1 are produced from multiple bicistronic mRNAs. J Virol 1990; 64(11):5448-5456.
13. Schwartz S, Felber BK, Pavlakis GN. Expression of human immunodeficiency virus type 1 vif and vpr mRNAs is Rev-dependent and regulated by splicing. Virology 1991; 183(2):677-686.
14. Fornerod M, Ohno M, Yoshida M et al. CRM1 is an export receptor for leucine-rich nuclear export signals [see comments]. Cell 1997; 90(6):1051-1060.
15. Hammarskjold ML, Heimer J, Hammarskjold B et al. Regulation of human immunodeficiency virus env expression by the rev gene product. J-Virol 1989; 63(5):1959-1966.
16. Malim MH, Hauber J, Le SY et al. The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 1989; 338(6212):254-257.
17. Malim MH, Tiley LS, McCarn DF et al. HIV-1 structural gene expression requires binding of the Rev trans-activator to its RNA target sequence. Cell 1990; 60(4):675-683.
18. Salahuddin SZ, Nakamura S, Biberfeld P et al. Angiogenic properties of Kaposi's sarcoma-derived cells after long-term culture in vitro. Science 1988; 242(4877):430-433.
19. Schwartz S, Felber BK, Pavlakis GN. Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein. J Virol 1992; 66(1):150-159.
20. Schwartz S, Campbell M, Nasioulas G et al. Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression. J Virol 1992; 66(12):7176-7182.
21. Arrigo SJ, Chen IS. Rev is necessary for translation but not cytoplasmic accumulation of HIV-1 vif, vpr, and env/vpu 2 RNAs. Genes Dev 1991; 5(5):808-819.
22. Butsch M, Hull S, Wang Y et al. The 5′ RNA terminus of spleen necrosis virus contains a novel posttranscriptional control element that facilitates human immunodeficiency virus Rev/RRE-independent Gag production. J Virol 1999; 73(6):4847-4855.
23. Lu XB, Heimer J, Rekosh D et al. U1 small nuclear RNA plays a direct role in the formation of a rev-regulated human immunodeficiency virus env mRNA that remains unspliced. Proc Natl Acad Sci USA 1990; 87(19):7598-7602.
24. Wills JW, Craven RC. Form, function, and use of retroviral gag proteins [editorial]. AIDS 1991; 5(6):639-654.
25. Smith AJ, Cho MI, Hammarskjold ML et al. Human immunodeficiency virus type 1 Pr55gag and Pr160gag-pol expressed from a simian virus 40 late replacement vector are efficiently processed and assembled into viruslike particles. J Virol 1990; 64(6):2743-2750.
26. Gheysen D, Jacobs E, de Foresta F et al. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell 1989; 59(1):103-112.
27. Delchambre M, Gheysen D, Thines D et al. The GAG precursor of simian immunodeficiency virus assembles into virus-like particles. EMBO J 1989; 8(9):2653-2660.
28. Jacobs E, Gheysen D, Thines D et al. The HIV-1 Gag precursor Pr55gag synthesized in yeast is myristoylated and targeted to the plasma membrane. Gene 1989; 79(1):71-81.
29. Karacostas V, Wolffe EJ, Nagashima K et al. Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles. Virology 1993; 193(2):661-671.
30. Karacostas V, Nagashima K, Gonda MA et al. Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. Proc Natl Acad Sci USA.1989; 86(22):8964-8967.
31. Hu SL, Travis BM, Garrigues J et al. Processing, assembly, and immunogenicity of human immunodeficiency virus core antigens expressed by recombinant vaccinia virus. Virology 1990; 179(1):321-329.
32. Shioda T, Shibuta H. Production of human immunodeficiency virus (HIV)-like particles from cells infected with recombinant vaccinia viruses carrying the gag gene of HIV. Virology 1990; 175(1):139-148.
33. Haffar O, Garrigues J, Travis B et al. Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system. J Virol 1990; 64(6):2653-2659.
34. Mergener K, Facke M, Welker R et al. Analysis of HIV particle formation using transient expression of subviral constructs in mammaliancells. Virology 1992; 186(1):25-39.
35. Bryant M, Ratner L. Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc Natl Acad Sci USA 1990; 87(2):523-527.
36. Smith AJ, Srinivasakumar N, Hammarskjold ML et al. Requirements for incorporation of Pr160gagpol rom human immunodeficiency virus type 1 into virus-like particles. J Virol 1993; 67(4):2266-2275.
37. Srinivasakumar N, Hammarskjold ML, Rekosh D. Characterization of deletion mutations in the capsid region of human immunodeficiency virus type 1 that affect particle formation and Gag-Pol precursor incorporation. J Virol 1995; 69(10):6106-6114.
38. Wang CT, Stegeman-Olsen J, Zhang Y et al. Assembly of HIV GAG-B-galactosidase fusion proteins into virus particles. Virology 1994; 200(2):524-534.
39. Park J, Morrow CD. The nonmyristylated Pr160gag-pol polyprotein of human immunodeficiency virus type 1 interacts with Pr55gag and is incorporated into viruslike particles. J Virol 1992; 66(11):6304-6313.
40. Paxton W, Connor RI, Landau NR. Incorporation of Vpr into human immunodeficiency virus type 1 virions: Requirement for the p6 region of gag and mutational analysis. J Virol 1993; 67(12):7229-7237.
41. Selig L, Pages J, Tanchou V et al. Interaction with the p6 domain of the gag precursor mediates incorporation into virions of vpr and vpx proteins from primate lentiviruses [In Process Citation]. J Virol 1999; 73(1):592-600.
42. Muller B, Tessmer U, Schubert U et al. Human immunodeficiency virus type 1 vpr protein is incorporated into the virion in significantly smaller amounts than gag and Is phosphorylated in infected cells [In Process Citation]. J Virol 2000; 74(20):9727-9731.
43. Khan MA, Aberham C, Kao S et al. Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA. J Virol 2001; 75(16):7252-7265.
44. Charneau P, Mirambeau G, Roux P et al. HIV-1 reverse transcription. A termination step at the center of the genome. J Mol Biol 1994; 241(5):651-662.
45. Follenzi A, Ailles LE, Bakovic S et al. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 2000; 25(2):217-222.
46. Zennou V, Petit C, Guetard D et al. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 2000; 101(2):173-185.
47. Trono D, Baltimore D. A human cell factor is essential for HIV-1 Rev action. EMBO J 1990; 9(12):4155-4160.
48. Verma IM, Somia N. Gene therapy - promises, problems and prospects. Nature 1997; 389(6648):239242.
49. Clever J, Sassetti C, Parslow TG. RNA secondary structure and binding sites for gaggene products in the 5′ packaging signal of human immunodeficiency virus type 1. J Virol 1995; 69(4):2101-2109.
50. Das AT, Klaver B, Klasens BI et al. Aconserved hairpin motif in the R-U5 region of the human immunodeficiency virus type 1 RNA genome is essential for replication. J Virol 1997; 71(3):2346-2356.
51. McBride MS, Panganiban AT. The human immunodeficiency virus type 1 encapsidation site is a multipartite RNA element composed of functional hairpin structures [published erratum appears in J Virol 1997 Jan;71(1):858]. J Virol 1996; 70(5):2963-2973.
52. McBride MS, Panganiban AT. Position dependence of functional hairpins important for human immunodeficiency virus type 1 RNA encapsidation in vivo. J Virol 1997; 71(3):2050-2058.
53. Helga-Maria C, Hammarskjold ML, Rekosh D. An intact TAR element and cytoplasmic localization are necessary for efficient packaging of human immunodeficiency virus type 1 genomic RNA. J Virol 1999; 73(5):4127-4135.
54. Clever JL, Parslow TG. Mutant human immunodeficiency virus type 1 genomes with defects in RNA dimerization or encapsidation. J Virol 1997; 71(5):3407-3414.
55. Luban J, Goff SP. Mutational analysis of cis-acting packaging signals in human immunodeficiency virus type 1 RNA. J Virol 1994; 68(6):3784-3793.
56. Bender MA, Palmer TD, Gelinas RE et al. Evidence that the packaging signal of Moloney murine leukemia virus extends into the gag region. J Virol 1987; 61(5):1639-1646.
57. Parolin C, Dorfman T, Palu G et al. Analysis in human immunodeficiency virus type 1 vectors of cis-acting sequences that affect gene transfer into human lymphocytes. J Virol 1994; 68(6):3888-3895.
58. Buchschacher GJ, Panganiban AT. Human immunodeficiency virus vectors for inducible expression of foreign genes. J Virol 1992; 66(5):2731-2739.
59. Naldini L, Blomer U, Gallay P et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272(5259):263-267.
60. Nasioulas G, Zolotukhin AS, Tabernero C et al. Elements distinct from human immunodeficiency virus type 1 splice sites are responsible for the Rev dependence of env mRNA. J Virol 1994; 68(5):2986-2993.
61. Cui Y, Iwakuma T, Chang LJ. Contributions of viral splice sites and cis-regulatory elements to lentivirus vector function. J Virol 1999; 73(7):6171-6176.
62. Rizvi TA, Panganiban AT. Simian immunodeficiency virus RNA is efficiently encapsidated by human immunodeficiency virus type 1 particles. J Virol 1993; 67(5):2681-2688.
63. Srinivasakumar N, Schuening FG. Novel Tat-encoding bicistronic human immunodeficiency virus type 1-based gene-transfer vectors for high-level transgene expression. J Virol 2000; 74:6659-6668.
64. Parolin P, Taddeo B, Palu G et al. Use of cis- and trans-Acting regulatory sequences to improve expression of human immunodeficiency virus vectors in human lymphocytes. Virology 1996; 222:415-422.
65. Salmon P, Kindler V, Ducrey O et al. High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors [In Process Citation] Blood 2000; 96(10):3392-3398.
66. Miyoshi H, Takahashi M, Gage FH et al. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc Natl Acad Sci USA 1997; 94(19):10319-10323.
67. DeZazzo JD, Kilpatrick JE, Imperiale MJ. Involvement of long terminal repeat U3 sequences overlapping the transcription control region in human immunodeficiency virus type 1 mRNA 3′ end formation. Mol Cell Biol 1991; 11(3):1624-1630.
68. DeZazzo JD, Scott JM, Imperiale MJ. Relative roles of signals upstrea of AAUAAA and promoter proximity in regulation of human immunodeficiency virus type 1 mRNA 3′ end formation. Mol Cell Biol 1992; 12(12):5555-5562.
69. Valsamakis A, Zeichner S, Carswell S et al. The human immunodeficiency virus type 1 polyadenylylation signal: A 3′ long terminal repeat element upstream of the AAUAAA necessary for efficient polyadenylylation. Proc Natl Acad Sci USA 1991; 88(6):2108-2112.
70. Iwakuma T, Cui Y, Chang LJ. Self-inactivating lentiviral vectors with U3 and U5 modifications. Virology 1999;261(1):120-132.
71. Zufferey R, Dull T, Mandel RJ et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72(12):9873-9880.
72. Mochizuki H, Schwartz JP, Tanaka K et al. High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells. J Virol 1998; 72(11):8873-8883.
73. Yee JK, Miyanohara A, LaPorte P et al. A general method for the generation of high-titer, pantropic retroviral vectors: Highly efficient infection of primary hepatocytes. Proc Natl Acad Sci USA 1994; 91(20):9564-9568.
74. Kiem HP, McSweeney PA, Bruno B et al. Improved gene transfer into canine hematopoietic repopulating cells using CD34-enriched marrow cells in combination with a gibbon ape leukemia virus-pseudotype retroviral vector. Gene Ther 1999; 6(6):966-972.
75. Stitz J, Buchholz CJ, Engelstadter M et al. Lentiviral vectors pseudotyped with envelope glycoproteins derived from gibbon ape leukemia virus and murine leukemia virus 10A1. Virology 2000; 273(1):16-20.
76. Chu TH, Dornburg R. Retroviral vector particles displaying the antigen-binding site of an antibody enable cell-type-specific gene transfer. J Virol 1995; 69(4):2659-2663.
77. Chu TH, Dornburg R. Toward highly efficient cell-type-specific gene transfer with retroviral vectors displaying single-chain antibodies. J Virol 1997; 71(1):720-725.
78. Jiang A, Chu TH, Nocken F et al. Cell-type-specific gene transfer into human cells with retroviral vectors that display single-chain antibodies. J Virol 1998; 72(12):10148-10156.
79. Martinez I, Dornburg R. Mapping of receptor binding domains in the envelope protein of spleen necrosis virus. J Virol 1995; 69(7):4339-4346.
80. Mardnez I, Dornburg R. Mutational analysis of the envelope protein of spleen necrosis virus. J Virol 1996; 70(9):6036-6043.
81. Naviaux RK, Costanzi E, Haas M et al. The pCL vector system: Rapid production of helper-free, high-titer, recombinant retroviruses. J Virol 1996; 70(8):5701-5705.
82. Srinivasakumar N et al. (unpublished observations).
83. Batra RK, Olsen JC, Hoganson DK et al. Retroviral gene transfer is inhibited by chondroitin sulfate proteoglycans/glycosaminoglycans in malignant pleural effusions. J Biol Chem 1997; 272(18):11736-11743.
84. Le Doux JM, Morgan JR, Snow RG et al. Proteoglycans secreted by packaging cell lines inhibit retrovirus infection. J Virol 1996; 70(9):6468-6473.
85. Le Doux JM, Morgan JR, Yarmush ML. Removal of proteoglycans increases efficiency of retroviral gene transfer. Biotechnol Bioeng 1998; 58(1):23-34.
86. Le Doux JM, Morgan JR, Yarmush ML. Differential inhibition of retrovirus transduction by proteoglycans and free glycosaminoglycans. Biotechnol Prog 1999; 15(3):397-406.
87. Reiser J. Production and concentration of pseudotyped HIV-1-based gene transfer vectors. Gene Ther 2000; 7(11):910-913.
88. Srinivasakumar N, Schuening F. A lentivirus packaging system based on alternative RNA transport mechanisms to express helper and gene transfer vector RNAs and its use to study the requirement of accessory proteins for particle formation and gene delivery. J Virol 1999; 73:9589-9598.
89. Albini A, Fontanini G, Masiello L et al. Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants and HIV-1 tat product: Inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2. AIDS 1994; 8(9):1237-1244.
90. Albini A, Barillari G, Benelli R et al. Angiogenic properties of human immunodeficiency virus type 1 Tat protein. Proc Nad Acad Sci USA 1995; 92(11):4838-4842.
91. Albini A, Benelli R, Presta M et al. HIV-tat protein is a heparin-binding angiogenic growthfactor. Oncogene 1996; 12(2):289-297.
92. Ensoli B, Barillari G, Salahuddin SZ et al. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 1990; 345(6270):84-86.
93. Ensoli B, Barillari G, Buonaguro L et al. Molecular mechanisms in the pathogenesis of AIDS-associated aposi's sarcoma. Adv Exp Med Biol 1991; 303:27-38.
94. Ensoli B, Buonaguro L, Barillari G et al. Release, uptake, and effects of extracellular human immunoeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 1993; 67(1):277-287.
95. Ensoli B, Gendelman R, Markham P et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature 1994; 371(6499):674-680.
96. Chirmule N, Than S, Khan SA et al. Human immunodeficiency virus Tat induces functional unresponsiveness in T cells. J Virol 1995; 69(1):492-498.
97. Ott M, Emiliani S, Van Lint C et al. Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway. Science 1997; 275(505):1481-1485.
98. Ott M, Lovett JL, Mueller L et al. Superinduction of IL-8 in T cells by HIV-1 Tat protein is mediated through NF-kappaB factors. J Immunol 1998; 160(6):2872-2880.
99. Puri RK, Leland P, Aggarwal BB. Constitutive expression of human immunodeficiency virus type 1 tat gene inhibits intrleukin 2 and interleukin 2 receptor expression in a human CD4+ T lymphoid (H9) cell line. AIDS Res Hum Retroviruses 1995; 11(1):31-40.
100. Rautonen N, Rautonen J, Martin NL et al. HIV-1 Tat induces cytokine synthesis by uninfected mononuclear cells [letter]. AIDS 1994; 8(10):1504-1506.
101. Reinhold D, Wrenger S, Bank U et al. CD26 mediates the action of HIV-1 Tat protein on DNA synthesis and cytokine production in U937 cells. Immunobiology 1996; 195(1):119-428.
102. Subramanyam M, Gutheil WG, Bachovchin WW et al. Mechanism of HIV-1 Tat induced inhibition f antigen-specific T cell responsiveness. J Immunol 1993; 150(6):2544-2553.
103. Vacca A, Farina M, Maroder M et al. Human immunodeficiency virus type-1 tat enhances interlekin-2 promoter activity through synergism with phorbol ester and calcium-mediated activation of the NF-AT cis-regulatory motif. Biochem Biophys Res Commun 1994; 205(1):467-474.
104. Verhoef K, Bauer M, Meyerhans A et al. On the role of the second coding exon of the HIV-1 Tat protein in virus replication and MHC class I downregulation. AIDS Res Hum Retroviruses 1998; 14(17):1553-1559.
105. Kaul M, Yu H, Ron Y et al. Regulated lentiviral packaging cell line devoid of most viral cis- acting sequences. Virology 1998; 249(1):167-174.
106. Gasmi M, Glynn J, Jin MJ et al. Requirements for efficient production and transduction of human immunodeficiency vius type 1-based vectors. J Virol 1999; 73(3):1828-1834.
107. Madani N, Kabat D. Cellular and viral specificities of human immunodeficiency virus type 1 vif protein. J Virol 2000; 74(13):5982-5987.
108. Simon JH, Miller DL, Fouchier RA et al. The regulation of primate immunodeficiency virus infectivity by Vif is cell species restricted: A role for Vif in determining virus host range and cross-species transmission. EMBO J 1998; 17(5):1259-1267.
109. von Schwedler U, Song J, Aiken C et al. Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol 1993; 67(8):4945-4955.
110. Strebel K, Klimkait T, Maldarelli F et al. Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein. J Virol 1989; 63(9):3784-3791.
111. Schwartz MD, Geraghty RJ, Panganiban AT. HIV-1 particle release mediated by Vpu is distinct from that mediated by p6. Virology 1996; 224(1):302-309.
112. Gottlinger HG, Dorfman T, Sodroski JG et al. Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci USA 1991;88(8):3195-3199.
113. Kerkau T, Bacik I, Bennink JR et al. The human immunodeficiency virustype 1 (HIV-1) Vpu protein interferes with an early step in the biosynthesis of major histocompatibility complex (MHC) class I molecules. J Exp Med 1997; 185(7):1295-1305.
114. Willey RL, Maldarelli F, Martin MA et al. Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol 1992; 66(12):7193-7200.
115. Bartz SR, Rogel ME, Emerman M. Human immunodficiency virus type 1 cell cycle control: Vpr is cytostatic and mediates G2 accumulation by a mechanism which differs from DNA damage checkpoint control. J Virol 1996; 70(4):2324-2331.
116. Rogel ME, Wu LI, Emerman M. The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. J Virol 1995; 69(2):882-888.
117. Re F, Braaten D, Franke EK et al. Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B. J Virol 1995; 69(11):6859-6864.
118. Goh WC, Rogel ME, Kinsey CM et al. HIV-1 Vpr increases viral expression by manipulation of the cell cycle: A mechanism for selection of Vpr in vivo. Nat Med 1998; 4(1):65-71.
119. Heinzinger NK, Bukinsky MI, Haggerty SA et al. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci USA 1994; 91(15):7311-7315.
120. Popov S, Rexach M, Zybarth G et al. Viral protein R regulates nuclear import of the HIV-1 preintegration complex. EMBO J 1998; 17(4):909-917.
121. Popov S, Rexach M, Ratner L et al. Viral protein R regulates docking of the HIV-1 preintegration complex to the nuclear pore complex. J Biol Chem 1998; 273(21):13347-13352.
122. Vodicka MA, Koepp DM, Silver PA et al. HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection. Genes Dev 1998; 2(2):175-185.
123. Stewart SA, Poon B, Jowett JB et al. Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle rrest. J Virol 1997; 71(7):5579-5592.
124. Stewart SA, Poon B, Jowett JB et al. Lentiviral delivery of HIV-1 Vpr protein induces apoptosi in transformed cells. Proc Natl Acad Sci USA 1999; 96(21):12039-12043.
125. Stewart SA, Poon B, Song JY et al. Human immunodeficiency virus type 1 vpr induces apoptosis through caspase activation. J Virol 2000; 74(7):3105-3111.
126. Chinnasamy D, Chinnasamy N, Enriquez MJ et al. Lentiviral-mediated gene transfer into human lymphocytes: Role f HIV-1 accessory proteins. Blood 2000; 96(4):1309-1316.
127. Anderson. SJ, Lenburg M, Landau NR et al. The cytoplasmic domain of CD4 is sufficient for its down-regulation from the cell surface by human immunodeficiency virus type 1 Nef [published erratum appears in J Virol 1994 Jul; 68(7):4705]. J Virol 1994; 68(5):3092-3101.
128. Aiken C, Konner J, Landau NR et al. Nef induces CD4 endoctosis: Requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. Cell 1994; 76(5):853-864.
129. Garcia JV, Miller AD. Downregulation of cell surface CD4 by nef. Res Virol 1992; 143(1):52-55.
130. Garcia JV, Miller AD. Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature 1991; 350(6318):508-511.
131. Luo T, Livingston RA, Garcia JV. Infectivity enhancement by human immunodeficiency virus type 1 Nef is independent of its association with a cellular serine/threonine kinase. J Virol 1997; 71(12):9524-9530.
132. Luo T, Douglas JL, Livingston RL et al. Infectivity enhancement by HIV-1 Nef is dependent on the pathway of virus entry: Implications for HIV-based gene transfer systems. Virology 1998; 241(2):224-233.
133. Srinivasakumar N, Chazal N, Helga-Maria C et al. The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines. J Virol 1997; 71(8):5841-5848.
134. Schwrtz O, Marechal V, Danos O et al. Human immunodeficiency virus tpe 1 Nef increases the efficiency of reverse transcription in the infected cell. J Virol 1995; 69(7):4053-4059.
135. Aiken C, Trono D. Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J Virol 1995; 69(8):5048-5056.
136. Aiken C. Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J Virol 1997; 71(8):5871-5877.
137. Chazal N, Singer G, Aiken C et al. Human immunodeficiency virus type 1 particles pseudotyped with envelope proteins that fuse at low pH no longer require Nef or optimal infectivity. J Virol 2001; 75(8):4014-4018.
138. Hanna Z, Kay DG, Rebai N et al. Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell 1998; 95(2):163-175.
139. Delwart EL, Buchschacher GL, Jr., Freed EO et al. Analysis of HIV-1 envelope mutants and pseudotyping of replication- defective HIV-1 vectors by genetic complementation. AIDS Res Hum Retroviruses 1992; 8(9):1669-1677.
140. Page KA, Landau NR, Littman DR. Construction and use of a human immunodeficiency virus vector foranalysis of virus infectivity. J Virol 1990; 64(11):5270-5276.
141. Collins KL, Chen BK, Kalams SA et al. HIV-1 Nef protin protects infected primary cells against killing by cytotoxic lymphocytes. Nature 1998; 391(6665):397-401.
142. Chen BK, Feinberg MB, Baltimore D. The kappaB sites in the human immunodeficiency virus type 1 long terminal repeat enhance virus replication yet are not absolutely required for viral growth. J Virol 1997; 71(7):5495-5504.
143. Kafri T, Blomer U, Peerson DA et al. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet 1997; 17(3):314-317.
144. Zufferey R, Nagy D, Mandel RJ et al. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15(9):871-875.
145. Dull T, Zufferey R, Kelly M et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72(11):8463-8471.
146. Ernst RK, Bray M, Rekosh D et al. A structured retroviral RNA element that mediates nucleocytoplasmic export of intron-containing RNA. Mol Cell Biol 1997; 17(1):135-144.
147. Ernst RK, Bray M, Rekosh D et al. Secondary structure and mutational analysis of the Mason-Pfizer monkey virus RNA constitutive transport element. Rna 1997; 3(2):210-222.
148. Bray M, Prasad S, Dubay JW et al. A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev- independent. Proc Natl Acad Sci USA 1994; 91(4):1256-1260.
149. Kim VN, Mitrophanous K, Kingsman SM et al. Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J Virol 1998; 72(1):811-816.
150. Mautino MR, Ramsey WJ, Reiser J et al. Modified human immunodeficiency virus-based lentiviral vectors display decreased sensitivity to trans-dominant Rev. Hum Gene Ther 2000;11(6):895-908.
151. Mautino MR, Keiser N, Morgan RA. Improved titers of HIV-based lentiviral vectors using the SRV-1 constitutive transport element. Gene Ther 2000; 7(16):1421-1424.
152. Zolotukhin AS, Valentin A, Pavlakis GN et al. Continuous propagation of RRE(-) and Rev(-)RRE(-) human immunodeficiency virus type 1 molecular clones containing a cis-acting element of simian retrovirus type 1 in human peripheral blood lymphocytes. J Virol 1994; 68(2):7944-7952.
153. Kotsopoulou E, Kim VN, Kingsman AJ et al. A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. J Virol 2000; 74(10):4839-4852.
154. White SM, Renda M, Nam NY et al. Lentivirus vectors using human and simian immunodeficiency virus elements. J Virol 1999; 73(4):2832-2840.
155. Wu X, Wakefield JK, Liu H et al. Development of a novel trans-lentiviral vector that affords predictable safety. Mol Ther 2000; 2(1:47-55.
156. Dougherty JP, Temin HM. A promoterlessretroviral vector indicates that there are sequences in U3 required for 3′ RNA processing. Proc Natl Acad Sci USA 1987; 84(5):1197-1201.
157. Yu SF, von Ruden T, Kantoff PW et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci USA 1986;83(10):3194-3198.
158. DeZazzo JD, Imperiale MJ. Sequences upstream of AAUAAA influence poly(A) site selection in a complex transcription unit. Mol Cell Biol 1989; 9(11):4951-4961.
159. Kung SK, An DS, Chen IS. A murine leukemia virus (MuLV) long terminal repeat derived from rhesus macaques in the context of a lentivirus vector and MuLV gag sequence results in high-level gene expression in human T lymphocytes. J Virol 2000; 74(8):3668-3681.
160. Emerman M, Temin HM. Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell 1984; 39(3 Pt 2):449-467.
161. Harrich D, Ulich C, Garcia-Martinez LF et al. Tat is required for efficient HIV-1 reverse transcription. EMBO J 1997;16(6):1224-1235.
162. McBride MS, Schwartz MD, Panganiban AT. Efficient encapsidation of human immunodeficiency virus type 1 vectors and further characterization of cis elements required for encapsidation. J Virol 1997;71(6):4544-4554.
163. Rizvi TA, Schmidt RD, Lew KA et al. Rev/RRE-independent Mason-Pfizer monkey virus constitutive trasport element-dependent propagation of SIVmac239 vectors using a single round of replication assay. Virology 1996;222(2):457-463.
164. Rizvi TA, Lew KA, Murphy EC, Jr. et al. Role of Mason-Pfizer monkey virus (MPMV) constitutive transport element (CTE) in the propagation of MPMV vectors by genetic complementation using homologous/heterologous env genes. Virology 1996; 224(2):517-532.
165. Rizvi TA, Schmidt RD, Lew KA. Mason-Pfizer monkey virus (MPMV) constitutive transport element (CTE) functions in a position-dependent manner. Virology 1997; 236(1):118-129.
166. Donello JE, Loeb JE, Hope TJ. Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element. J Virol 1998; 72(6):5085-5092.
167. Zufferey R, Donello JE, Trono D et al. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 1999; 73(4):2886-2892.
168. May C, Rivella S, Callegari J et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature 2000; 406(6791):82-86.
169. Kordower JH, Emborg ME, Bloch J et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000; 290(5492):767-773.
170. Corbeau P, Wong-Staal F. Anti-HIV effects of HIV vectors. Virology 1998; 243(2):268-274.
171. Bukovsky AA, Song JP, Naldini L. Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells. J Virol 1999; 73(8):7087-7092.
172. Lorincz MC, Schubeler D, Goeke SC et al. Dynamic analysis of proviral induction and De Novo methylation: Implications for a histone deacetylase-independet, methylation ensity-dependent mechanism of transcriptional repression. Mol Cell Biol 2000; 20(3):842-850.
173. Cherry SR, Biniszkiewicz D, van Parijs L et al. Retroviral expression in embryonic stem cells and hematopoietic stem cells. Mol Cell Biol 2000; 20(20):7419-7426.
174. Chen WY, Townes TM. Molecular mechanism for silencing virally transduced genes involves histone deacetylation and chromatin condensation. Proc Natl Acad Sci USA 2000; 97(1):377-382.
175. Chen WY, Bailey EC, McCune SL et al. Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase. Proc Natl Acad Sci USA 1997; 94(11):5798-5803.
176. Naldini L, Blomer U, Gage FH et al. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996; 93(21):11382-11388.
177. Blomer U, Naldini L, Kafri T et al. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol 1997; 71(9):6641-6649.
178. Hamaguchi I, Woods NB, Panagopoulos I et al. Lentivirus vector gene expression during ES cell-derived hematopoietic development in vitro. J Virol 2000; 74(22):10778-10784.
179. Agarwal M, Austin TW, Morel F et al. Scaffold attachment region-mediated enhancement of retroviral vector expression in primary T cells. J Virol 1998; 72(5):3720-3728.
180. Auten J, Agarwal M, Chen J et al. Effect of scaffold attachment region on transgene expression in retrovirus vector-transduced primary T cells and macrophages. Hum Gene Ther 1999; 10(8):1389-1399.
181. Dang Q, Auten J, Plavec I. Human beta interferon scaffold attachment region inhibits de novo methylation and confers long-term, copy number-dependent expression to a retroviral vector. J Virol 2000; 74(6):2671-2678.
182. Kafri T, van Praag H, Gage FH et al. Lentiviral vectors: Regulated gene expression. Mol Ther 2000; 1(6):516-521.
183. Shockett PE, Schatz DG. Diverse strategies for tetracycline-regulated inducible gene expression. Proc Natl Acad Sci USA 1996; 93(11):5173-5176.
184. Deuschle U, Meyer WK, Thiesen HJ. Tetracycline-reversible silencing of eukaryotic promoters. Mol Cell Biol 1995; 15(4):1907-1914.
185. Hofmann A, Nolan GP, Blau HM. Rapid retroviral delivery of tetracycline-inducible genes in a single autoregulatory cassette. Proc Natl Acad Sci USA 1996; 93(11):5185-5190.
186. Paulus W, Baur I, Boyce FM et al. Self-contained, rettacycline-regulated retroviral vector system for gene delivery to mammalian cells. J Virol 1996; 70(1):62-67.
187. Rivera VM, Clackson T, Natesan S et al. A humanized system for pharmacologic control of gene expression [see comments]. Nat Med 1996; 2(9):1028-1032.
188. Spencer DM, Wandless TJ, Schreiber SL et al. Controlling signal transduction with synthetic ligands [see comments]. Science 1993; 262(5136):1019-1024.
189. Braselmann S, Graninger P, Busslinger M. A selective transcriptional induction system for mammalian cells based on Gal4-estrogen receptor fusion proteins. Proc Natl Acad Sci USA 1993; 90(5):1657-1661.
190. Wang Y, O'Malley BW, Jr., Tsai SY et al. A regulatory system for use in gene transfer. Proc Natl Acad Sci USA 1994; 91(17):8180-8184.
191. Whelan J, Miller N. Generation of estrogen receptor mutants with altered ligand specificity for use in establishing a regulatable gene expression system. J Steroid Biochem Mol Biol 1996; 58(1):3-12.
192. Bushman FD. Tethering human immunodeficiency virus 1 integrase to a DNA site directs integration to nearby sequences. Proc Natl Acad Sci USA 1994; 91(20):9233-9237.
193. Goulaouic H, Chow SA. Directed integration of viral DNA mediated by fusion proteins consisting of human immunodeficiency virus type 1 integrase and Escherichia coli LexA protein. J Virol 1996; 70(1):37-46.
194. Re F, Luban J. HIV-1 Vpr: G2 cell cycle arrest, macrophages and nuclear transport. Prog Cell Cycle Res 1997; 3:21-27.
195. Krausslich HG, Ochsenbauer C, Traenckner AM et al. Analysis of protein expression and virus-like particle formation in mammalian cell lines stably expressing HIV-1 gag and env gene products with or without active HIV proteinase. Virology 1993; 192(2):605-617.
196. Shoeman RL Honer B, Stoller TJ et al. Cleavage of the intermediate filament subunit protein vimentin by HIV-1 protease: Utilization of a novel cleavage site and identification of higher order polymers of pepstatin A. Adv Exp Med Biol 1991; 306:533-537.
197. Shoeman RL, Mothes, Honer B et al. Effect of human immunodeficiency virustype 1 protease on the intermediate filament subunit protein vimentin: Cleavage, in vitro assembly and altered distribution of filaments in vivo following micrinjection of protease. Acta Histochem Suppl 1991; 41:129-141.
198. Corbeau P, Kraus G, Wong-Staal F. Efficient gene transfer by a human immunodeficiency virus type 1 (HIV-1)-derived vector utilizing a stable HIV packaging cell line. Proc Natl Acad Sci USA 1996; 93(24):14070-14075.
199. Corbeau P, Kraus G, Wong-Staal F. Transduction of human macrophages using a stable HIV-1/HIV-2-derived gene delivery system. Gene Ther 1998; 5(1):99-104.
200. Kafri T, van Praag H, Ouyang L et al. A packaging cell line for lentivirus vectors. J Virol 1999; 73(1):576-84.
201. Xu K, Ma H, McCown TJ et al. Geneation of a stable cell line producing high-titer self-inactivating lentiviral vectors. Mol Ther 2001; 3(1):97-104.
202. Howcroft TK, Strebel K, Martin MA et a. Reprssion of MHC class I gene promoter activity by two-exon Tat of HIV. Science 1993; 260(5112):1320-1322.
203. Kanazawa S, Okamoto T, Peterlin BM. Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection [In Process Citation]. Immunity 2000; 12(1):61-70.
204. An DS, Wersto RP, Agricola BA et al. Marking and gene expression by a lentivirus vector in transplanted human and nonhuman primate CD3(+) cells. J Virol 2000; 74(3):1286-1295.
205. Wilson CA, Ng TH, Miller AE. Evaluation of recommendations for replication-competent retrovirus testing associated with use of retroiral vectors. Hum Gene Ther 1997; 8(7):869-874.
206. Haas DL, Case SS, Crooks GM et al. Critical factors influencing stable transduction of human CD34(+) cells with HIV-1-derived lentiviral vectors. Mol Ther 2000; 2(1):71-80.
207. Kimpton J, Emerman M. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol 1992; 66(4):2232-2239.
208. Mann DA, Mikaelian I, Zemmel RW et al. A molecular rheostat. Co-operative rev bindng to stem I of the rev-response element modulates human immunodeficiency virus type-1 late gene expression. J Mol Biol 1994; 241(2):193-207.